Wall Street Zen Downgrades Genmab A/S (NASDAQ:GMAB) to Buy

Genmab A/S (NASDAQ:GMAB) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Tuesday, September 23rd. Zacks Research upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Genmab A/S in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Price Performance

GMAB opened at $33.17 on Friday. The company has a market cap of $21.30 billion, a price-to-earnings ratio of 16.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.98. The firm has a 50 day simple moving average of $27.95 and a 200 day simple moving average of $23.33. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $33.65.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Foresight Group Ltd Liability Partnership acquired a new position in Genmab A/S during the first quarter worth $954,000. Vident Advisory LLC acquired a new position in Genmab A/S during the first quarter worth $242,000. Wealth Enhancement Advisory Services LLC acquired a new position in Genmab A/S during the second quarter worth $257,000. DAVENPORT & Co LLC boosted its holdings in Genmab A/S by 6.8% during the second quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company’s stock worth $699,000 after purchasing an additional 2,147 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Genmab A/S by 377.5% during the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock worth $77,000 after purchasing an additional 2,941 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.